- Home
- RENB
as 09-17-2025 2:35pm EST
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | SUITE 906 LOS ANGELES |
| Market Cap: | 57.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 993.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.17 - $2.10 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Renovaro Biosciences Inc. News
RENB Breaking Stock News: Dive into RENB Ticker-Specific Updates for Smart Investing
ACCESS Newswire
9 days ago
Lunai Bioworks Strengthens European Strategy Through Restructuring
ACCESS Newswire
13 days ago
Lunai Bioworks Inc. Retains American Defense International
GlobeNewswire
3 months ago
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Insider Monkey
4 months ago
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
GlobeNewswire
4 months ago
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire
4 months ago
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire
4 months ago
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
GlobeNewswire
4 months ago
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
Compare RENB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RENB Renovaro Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.